Mahindra & Mahindra, Dr. Reddy's and Vedanta to see some action today

Dr. Reddys Laboratories Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500124 | NSE: DRREDDY

13 Apr 2021 Evaluate

Mahindra & Mahindra’s (M&M) all new Thar has crossed 50,000 bookings, within just six months of its launch. With its design, performance, off-road capability, everyday-comfort, technology and safety, the all-new Thar continues to attract not only die-hard enthusiasts, but urban lifestyle-seekers as well.

Dr. Reddy's Laboratories has received approval from expert panel for emergency use of Russia's covid-19 vaccine Sputnik V in the India, with certain conditions. The Drugs Controller General of India (DCGI) will take a final call on the recommendation. If approved, it will be the third covid-19 vaccine to be available in India. The vaccine would be imported from Russia for emergency use in the country.

Vedanta, India’s largest producer of aluminium and its value-added products, has signed a memorandum of understanding (MoU) for value-creation from bauxite residue (red mud), which is a by-product generated during processing of bauxite into alumina using the Bayer process.

Axis Bank’s customers can now send money abroad in over 100 currencies through their mobile application. By using 'Send Money Abroad' feature in Axis Mobile App, the customers will be able to send money by following a simple two-step process given on the app.

The demerger process of NMDC's Nagarnar Steel Plant (NSP) in Chhattisgarh into a separate entity is expected to be completed by August-September of this year. NSP is a 3 million tonne per annum (mtpa) integrated steel plant being set up by country's largest iron ore miner NMDC at Nagarnar in Chhattisgarh over an area of 1,980 acres at a revised estimated cost of Rs 23,140 crore. The demerger is in process and it is expected to be completed by August-September 2021.

Satin Creditcare Network’s Assets Under Management (AUM) has stood at Rs 7,274 crore in Q4FY21, a growth of 5.3% Quarter on quarter (QoQ), indicating that the growth has started kicking in. For FY21, the Company maintained sufficient liquidity of Rs 1,469 crore. During FY21, the Company raised Rs 4,312 crore including Direct Assignment Transactions of Rs 743 crore.

Markets regulator Sebi has imposed a penalty of Rs 25 crore on Yes Bank in the matter of misselling the lender's AT-1 bonds few years ago. Besides, the watchdog has imposed a fine of Rs 1 crore on Vivek Kanwar, who was the head of the private wealth management team, and Rs 50 lakh each on Ashish Nasa and Jasjit Singh Banga. The two individuals were part of the private wealth management team at the time of violation.

Dr. Reddys Labs. Share Price

1356.85 -19.45 (-1.41%)

30-Jun-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma. Inds.	1862.70
Dr. Reddys Labs.	1356.85
Cipla	1465.15
Zydus Lifesciences	1112.20
Lupin	2420.15
View more..

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.